Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 23, 2026

Tenable, PagerDuty, and HubSpot Shares Are Falling, What You Need To Know

View original at finance.yahoo.com
Tenable, PagerDuty, and HubSpot Shares Are Falling, What You Need To Know Tenable, PagerDuty, and HubSpot Shares Are Falling, What You Need To Know What Happened?…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI is compressing demand for traditional IT services, directly reducing billable hours at Accenture.

    60% confidence
  • Salesforce is a Rule-of-40 company, retiring 10% of its shares through a $25 billion buyback and carries the largest AI revenue line in the CRM category.

    60% confidence
  • Market fear persists that AI agents will erode the subscription model underpinning traditional enterprise software economics.

    60% confidence
  • The sector-wide software selloff was indiscriminate, driven mechanically by the index weight of Alphabet and Microsoft.

    60% confidence
  • Software stocks may remain in the penalty box until companies can prove AI revenue scales faster than it erodes the legacy subscription base.

    60% confidence
  • Salesforce is acquiring m3ter precisely to monetize AI agent actions rather than seats, positioning itself for a usage-based revenue transition.

    60% confidence
  • Salesforce is a Buy on valuation.

    60% confidence
  • The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

    60% confidence
  • The market is pricing AI cannibalization of legacy software as if it has already happened, but income statements may indicate otherwise.

    60% confidence
  • Adobe has not traded this cheaply on an earnings basis in over a decade.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com